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The human gastrointestinal tract is inhabited by a diverse and dense symbiotic microbiota, the 
composition of which is the result of host–microbe co-evolution and co-adaptation. This tight 
integration creates intense cross-talk and signaling between the host and microbiota at the 
cellular and metabolic levels. In many genetic or infectious diseases the balance between host 
and microbiota may be compromised resulting in erroneous communication. Consequently, the 
composition of the human metabolome, which includes the gut metabolome, may be different 
in health and disease states in terms of microbial products and metabolites entering systemic 
circulation. To test this hypothesis, we measured the level of hydroxy, branched, cyclopropyl and 
unsaturated fatty acids, aldehydes, and phenyl derivatives in blood of patients with a hereditary 
autoinflammatory disorder, familial Mediterranean fever (FMF), and in patients with peptic 
ulceration (PU) resulting from Helicobacter pylori infection. Discriminant function analysis of 
a data matrix consisting of 94 cases as statistical units (37 FMF patients, 14 PU patients, and 
43 healthy controls) and the concentration of 35 microbial products in the blood as statistical 
variables revealed a high accuracy of the proposed model (all cases were correctly classified). 
This suggests that the profile of microbial products and metabolites in the human metabolome 
is specific for a given disease and may potentially serve as a biomarker for disease.
Keywords: familial Mediterranean fever, peptic ulcer, metabolome, gas chromatography/mass spectrometry, microbial 
fatty acids, phenolic compounds, discriminant function analysis
We demonstrated recently that in an autoinflammatory disorder, 
familial Mediterranean fever (FMF, MIM249100), the commensal 
gut microbiota composition is specifically restructured and that 
the observed structural changes are determined by the host geno-
type (Khachatryan et al., 2008). This disease, which is caused by 
mutations in the MEFV gene, is characterized by periodic attacks 
of acute inflammation and fever, followed by periods of remission 
without any clinical sign of disease (The French FMF Consortium, 
1997; The International FMF Consortium, 1997). However, the 
elevated levels of cytokines and C-reactive protein in remission 
suggest the persisting subclinical inflammation (Manukyan et al., 
2008a). In the present work, we attempted to extend the investiga-
tion beyond structural analysis of the gut microbial community 
and establish if the restructured gut microbiota affects the human 
systemic metabolome.
Patients with peptic ulcer (PU) due to Helicobacter pylori infec-
tion were chosen as a comparative disease model for this metabo-
lomic study because it is a GIT inflammatory disease of known 
infectious nature. Although there is a contributory role of host 
genetics in the disease outcome (Snaith and El-Omar, 2008) the 
infection itself is a major driving force in development of the disease 
(Makola et al., 2007). Cultivation-independent studies revealed a 
much higher microbial diversity in the healthy stomach than pre-
viously thought (Bik et al., 2006). Infection by this well-adapted 
IntroductIon
The human gastrointestinal tract (GIT) represents the main site 
where intensive cross-talk takes place between the host and the 
immense, diverse commensal microbiota. In this host–microbe 
dialog (Bäckhed et al., 2005; Sartor, 2006) microbial components 
and metabolites are important biomolecules, contributing to the 
structural and functional stability in the complex GIT environ-
ment (Zoetendal et al., 2008). Many disorders in humans are 
due to a restructured microbiota, which fails to “communicate” 
properly with its host thus leading to aberrant host responses 
and contributing to the disease state (Farthing, 2004; Stecher and 
Hardt, 2008).
Much less, however, is known about the metabolic events along 
the gut microbiota–metabolite–host signal chain associated with 
the risk of inflammation and subsequent host disease. There is 
evidence suggesting that gut microbiota alterations correlate with 
a wide spectrum of human diseases, both within and outside the 
GIT (Frank et al., 2007; Adams et al., 2008; Jia et al., 2008). Even 
if a disease results from a genetic predisposition, the normal gut 
microbiota may be transformed into a “pathobiota” inflicting 
the disease on a genetically resistant host (Garrett et al., 2007). 
Structural changes in the gut microbiota in disease are predictably 
accompanied by changes in the gut metabolome (Jansson et al., 
2009) but the role of these metabolites in disease remains elusive.
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acid methanolysis using 1 M HCl in methanol. As a result, fatty acids 
and aldehydes were extracted from complex lipids of microorgan-
isms in the form of methyl esters and aldehyde dimethyl acetals. 
Internal standard, deuteromethyl ether of tridecane acid, prepared 
in hexane, was added to the cooled reaction mixture at 300 ng. The 
fraction of methyl esters of fatty acids with other lipid components 
was extracted twice from the reaction mixture with 200 μl of hex-
ane. Phenyl-carbonic acids were extracted from the acidified whole 
blood (pH 2.0) with diethyl ester. The hexane and ester extracts 
were dried at 40°C, and the dry residue was treated with 20 μl of 
N,O-bis-(trimethylsilyl)trifluoroacetamide for 15 min at 80°C to 
form trimethylsilyl derivatives of hydroxy acids (Beloborodova and 
Osipov, 2000).
Gc/MS analySIS
A GC/MS system (Agilent AT-5973, Agilent Technologies) with a 
cross-linked methyl silicone capillary column (DB-5 ms EVDX; 
dimensions: 0.2 mm × 25 m × 0.33 mkm, Agilent Technologies) was 
used to identify microbial components and metabolites in blood. 
Two microliters of the samples derived were injected into the capil-
lary column. Fatty acids and other lipid components separated in 
the GC column were analyzed in the selected ion-monitoring (SIM) 
mode (multi-ion mass-fragmentography regimen). The substances 
eluted were identified by measuring the specific retention times 
and the ratio of chromatographic peak areas for selected ions were 
measured primarily in automatic mode by using standard library 
search program (NIST 02 MS library), with subsequent manual 
checking of peaks. Correlation between the products identified 
and the corresponding source microorganisms was carried out as 
described before (Osipov and Turova, 1997; Osipov et al., 2009) 
using the Sherlock® microbial identification system (MIS; www.
midi-inc.com).
StatIStIcal analySIS
Statistical analysis was performed using the SPSS package (SPSS 
Inc., Chicago, IL, USA). Mann–Whitney U-test was applied to 
determine statistical significance among the mean values of studied 
groups. p-Values below 0.05 were considered statistically significant. 
Discriminant function analysis (DA) was used to classify cases into 
groups. The investigated groups of subjects were taken as depend-
ent variables of DA, and microbial substances and metabolites in 
blood were taken as predictors.
reSultS
The GC/MS approach was used in this study to detect and evaluate 
the concentration of products of microbial origin in blood of FMF 
(remission and attack) and PU patients compared to healthy control 
subjects (Table 1). For convenience, the chemically related structural 
compounds of microorganisms are placed together and presented 
as groups of hydroxy, branched, cyclopropyl and unsaturated acids, 
and aldehydes. Phenolic compounds, which are mostly the products 
of microbial metabolism, are presented as a separate group. Putative 
microbial sources of particular compounds are also shown.
Hydroxy fatty acIdS
Significantly higher levels of hydroxy acids were detected in blood 
of PU patients and FMF patients in remission compared with 
healthy controls, whereas in an FMF attack it was found to be 
pathogen drastically reduces microbial diversity and it becomes 
the dominant species in this ecological niche (Andersson et al., 
2008). The H. pylori colonization induces a chronic inflammatory 
response with the risk of a broad range of the upper GIT disor-
ders, including gastritis, PU, gastric cancer, and mucosa-associated 
lymphoid tissue lymphoma (Israel and Peek, 2006; Amieva and 
El-Omar, 2008). Using this disease model, it is possible to discover 
if the changes in the metabolome are attributable to the products of 
a single infective agent or if the situation is more complex. Whilst 
the role of H. pylori as an initiator of inflammation, as well as a 
modifier of the microbial environment is evident, the influence 
of its colonization of the gut on the host metabolome remains 
largely uncharacterized.
The rapidly developing field of metabolomics is an essential part 
of understanding the functionality of complex biological systems. 
The application of highly automated sequencing methodologies has 
tremendously changed the landscape of biological and biomedical 
research. However, in the post-genomic era the wealth of genotype 
information has to be complemented by phenotype characteriza-
tion because it is only at this level that it is possible to assess the 
outcome of genotype–environment interaction. In gut microbiol-
ogy, for example, a wealth of information is accumulated about 
the structure of microbial communities and the corresponding 
gene repertoires in health and disease. Much less is known, though, 
about the outcome of such genotypic differences at a mechanistic 
level. Metabolomics attempts to comprehensively analyze small 
molecules characterizing intact biological systems and in this regard 
mass spectrometry (MS) is the method of choice for metabolomic 
studies because it allows highly robust, reproducible, and sensitive 
qualitative or quantitative analysis (Koal and Deigner, 2010).
In this work, two disease states, FMF and PU, were studied using 
the gas chromatography/mass spectrometry (GC/MS) technique 
to analyze microbial products and metabolites encountered in sys-
temic circulation. The profile of hydroxy, branched, cyclopropyl 
and unsaturated fatty acids, aldehydes, and phenyl derivatives in 
these two diseases was distinct from the healthy state and was also 
disease-specific.
MaterIalS and MetHodS
SubjectS
A total of 37 FMF patients (13 in remission and 24 in attack peri-
ods), 14 PU patients in exacerbation period, and 43 healthy con-
trols participated in the study. All FMF cases were diagnosed based 
on Tel-Hashomer criteria with further genetic confirmation of 
MEFV mutations. All PU patients were diagnosed based on clinical 
symptoms (pain or discomfort in the upper abdomen, dyspepsia, 
bloating, an early sense of fullness after eating, acid reflux, lack of 
appetite, nausea, water brash, vomiting, blood in stool), and were 
H. pylori-positive by H. pylori breath test. The control group com-
prised of healthy volunteers without family history of FMF or any 
previously diagnosed PU disease. All study participants gave their 
informed consent to the protocol, which was approved by the local 
ethical committee at IMB NAS RA.
SaMple preparatIon
Blood samples for GC/MS analysis were collected into sterile 
heparinized vials and immediately frozen at −20°C until analysis. 
Defrosted blood samples were air dried at 80°C and subjected to 
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Table 1 | Concentration of compounds and their potential microbial source in blood of FMF and PU patients and healthy controls.
Substance Potential microbial sourcea Healthy controls FMF remission FMF attack PU patients
Hydroxy FaTTy aCidS (Fa)
2-Hydroxy lauric 
(2hC12:0)b
Pseudomonas aeruginosa, 
Acinetobacter
0.90c (0.70–1.10) 2.4 (1.5–3.9)*# 1.35 (0.75–1.75)*†# 2.35 (1.55–2.50)*
3-Hydroxy lauric 
(3hC12:0)
Pseudomonas, Moraxella, 
Acinetobacter
2.70 (2.00–3.65) 4.5 (4.0–5.9)*# 2.15 (1.18–3.35)†# 5.30 (3.44–6.03)*
3-Hydroxy stearic 
(3hC18:0)
Helicobacter pylori 11.3 (9.2–16.0) 40.9 (19.7– 50.4)*# 12.0 (9.88–36.4)†# 39.35 (34.4–44.1)*
10-Hydroxy stearic 
(10hC18:0)
Clostridium perfringens 27.4 (16.7–36.45) 61.8 (43.9–71.6)*# 30.1 (21.7–46.2)†# 65.2 (50.3–73.73)*
BranCHed Fa
Iso-myristic (iC14:0) Peptostreptococcus, Streptomyces, 
Bacillus, Bacteroides
69.8 (50.7–108.8) 70.6 (54.9–100.5)† 53 (39.9–85.3)† 139 (99–204)*
Iso-pentadecanoic 
(iC15:0)
Propionibacterium, Bacteroides, 
Staphylococcus
366.4 (292–621) 429 (237–480)† 286 (221–511)† 783 (442–1023)*
Iso-palmitic (iC16:0) Streptomyces, Bacteroides, 
Micromonospora
1193 (862–1563) 1330 (804–1457)† 1052 (796–1343)† 1863 (1470–2309)*
Iso-heptadecanoic 
(iC17:0)
Bacillus, Prevotella, 
Propionibacterium, Staphylococcus
2794 (1824–3921) 2902 (2655–3749)† 2567 (1902–3636)† 4275 (3470–5868)*
Iso-stearic (iC18:0) Peptostreptococcus, Clostridium 
difficile, Bifidobacterium
26.7 (16.75–36.5) 69.4 (45.7–112.9)* 43.2 (25.3–121.8)*† 100.9 (90.15–130.4)*
Anteiso-pentadecanoic 
(aC15:0)
Staphylococcus, Bacillus, 
Corynebacterium
377 (316–607) 411 (336–628)† 319 (270–563)† 858 (487–1228)*
Anteiso-heptadecanoic 
(aC17:0)
Corynebacterium, Bacteroides, 
Micromonospora, Staphylococcus
1601 (1215–2232) 1879 (1332–2131)† 1542 (1052–2108)† 2943 (2517–3955)*
Anteiso-nonadecanoic 
(aC19:0)
Staphylococcus 179 (136–213) 205 (174–212)† 176 (143–216)† 123.5 (97.9–137.5)*
CyCloProPyl Fa
Cyclopropyl 
heptadecanoic (C17cyc)
Enterobacteriaceae, Pseudomonas, 
Alcaligenes
1.60 (1.05–2.25) 5.0 (4.2–5.9)*† 2.50 (1.73–5.80)*† 10.35 (7.88–23.38)*
Cyclopropyl 
nonadecanoic (C19cyc)
Lactobacillus, Enterococcus 19.9 (13.05–32.7) 53.7 (42.3–112.4)*# 28.5 (19.6–98.9)*# 49.95 (40.53–70.95)*
UnSaTUraTed Fa
cis-9-tetradecenoic 
(C14:1d9)§
Clostridium 20.00 (7.45–28.75) 17.6 (8.3–29.6) 9.20 (6.10–18.55)* 11.65 (9.23–18.42)
cis-11-tetradecenoic 
(C14:1d11)
Nocardia 142 (78–364) 167 (130–200)†# 74.7 (50.7–124.5)*†# 297 (206–429)
cis-9-pentadecanoic 
(C15:1d9)
Clostridium propionicum, 
Bacteroides hypermegas
8.30 (5.00–15.15) 8.0 (6.5–23.3)† 5.60 (4.65–11.93) 5.1 (3.6–6.4)*
cis-7-hexadecenoic 
(C16:1d7)
Clostridium ramosum, C. innocuum, 
C. clostridioforme
1054 (859–1290) 955 (741–1082) 835 (617–994)*† 964 (868–1227)
cis-11-hexadecenoic 
(C16:1d11)
Ruminococcus, Nocardia, 
Fusobacterium
157 (110–236) 189 (129–200)†# 108 (80–156)*†# 238 (189–284)*
cis-9-heptadecenoic 
(C17:1d9)
Candida albicans 210 (149–301) 414 (336–691)* 280 (212–501)†* 596 (483–921)*
cis-11-octadecenoic 
(C18:1d11)
Bacteroides, Fusobacterium, 
Enterobacteriaceae, Pseudomonas, 
Streptococcus, Lactobacillus
4594 (2655–5915) 4372 (3897–5595)† 4445 (3203–5452)† 7605 (6798–10102)*
cis-9-eicosenoic 
(C20:1d9)
Propionibacterium jensenii, 
Actinomyces
840 (725–954) 920 (851–1044)*# 775 (645–862)†# 1072 (866–1243)*
cis-11-eicosenoic 
(C20:1d11)§
P. jensenii, Actinomyces, 
Streptococcus
72.2 (54.6–100.9) 81.4 (74.4–100.8)†# 63.2 (50.5–81.7)# 57.7 (38.0–77.5)
(Continued)
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states. Cyclopropyl nonadecanoic acid, which is associated with 
Lactobacillus and Enterococcus showed a similar tendency for eleva-
tion in all diseases studied.
brancHed fatty acIdS
Unidirectional inter-cohort alterations were observed for the 
branched fatty acids studied, which are mostly the components of 
commensal microbiota. In particular, the average levels of these acids 
were not significantly different between FMF remission and the nor-
mal controls, and tended to be less represented in blood of acute FMF 
patients compared to healthy subjects; whereas high concentrations 
of these compounds were associated with PU disorder. The correla-
tion of these acids with their potential microbial source is evidence of 
elevated content of such bacteria as Peptostreptococcus, Streptomyces, 
Bacillus, Bacteroides, Propionibacterium, and Micromonospora in PU 
disorders. The only exceptions to this tendency were observed in 
the case of iso-stearic (i18) and anteiso-nonadecanoic (a19) acids. 
The latter was detected in significantly lower concentrations in PU 
patients compared to other groups. Concentrations of iso-stearic 
acid were found to be higher in samples from both FMF and PU 
patients compared to controls.
comparable with the controls, except for 2-hydroxy lauric acid. 
Further comparison among the diseased cohorts revealed a sig-
nificant reduction of these substances in acute FMF patients 
compared to either FMF patients in remission or in PU patients. 
The corresponding values between FMF patients in remission 
and in PU patients were not significantly different. Surprisingly, 
no difference in concentration of H. pylori marker, 3-hydroxy 
stearic acid, was found between the FMF remission and PU dis-
eases, whilst these values exceeded the normal controls by up 
to four-fold. A similar tendency, with a two-fold increase, was 
also observed in the case of 10-hydroxy stearic acid, a refer-
ence marker for Clostridium perfringens. It is important to note 
that 2-hydroxy lauric and 3-hydroxy lauric acids are the signa-
ture compounds of non-fermentative Gram-negative bacteria 
(NFB; Table 1).
cyclopropyl fatty acIdS
In all three disease cohorts the concentration of cyclopropyl hep-
tadecanoic acid (17cyc) was significantly higher compared to the 
norm (Table 1). It is also a signature compound of NFB further 
supporting the overrepresentation of this group in these diseased 
aldeHydeS
Iso-myristic (iC14A) 92.6 (57.4–131.3) 69.2 (65.2–77.6)† 106.3 (78.8–131.3) 84.6 (78.2–128.0)
Myristic (C14A) Eubacterium lentum, 
Bifidobacterium bifidum
85.3 (61.3–134.0) 102.0 (66.4–136.0)† 95.5 (81.6–118.4)† 173 (136–249)*
Anteiso-pentadecanoic 
(aC15A)
Eubacterium, Peptostreptococcus 119 (75–184) 102 (83–164) 105.1 (85.6–152.8) 89.4 (79.8–120.4)
Iso-palmitic (iC16A) E. lentum 386 (278–538) 352 (249–372)# 462 (339–585)# 466 (309–568)
anteiso-heptadecanoic 
(aCa17A)
E. lentum, Propionibacterium acnes 1014 (688–1474) 788 (724–901)†# 1287 (959–1807)# 1454 (836–1710)
Oleic (C18:1d9A) Eubacterium moniliforme, 
Streptococcus mutans, Clostridium, 
B. bifidum, Propionibacterium, 
Peptostreptococcus
11518 (9277–13406) 9110 (7882–9278)†* 9502 (8300–11835) 11267 (9647–14147)
cis-vaccenic 
(C18:1d11A)
E. moniliforme, S. mutans, C. 
ramosum
4072 (3260–5252) 3219 (2101–3631)* 3217 (2470–4595) 3190 (2881–4116)*
PHenoliC CoMPoUndS
Benzoic acid 104 (75.3–144.9) 210 (138–283)* 185 (93–315)* 230 (224–276)*
3-Phenylpropionic acid 99.2 (49.6–167.0) 70.4 (44.0–120.7)† 63.5 (16.7–113.2)* 24.7 (17.1–41.3)*
Phenylacetic acid 66.8 (25.4–141.5) 66.2 (0.0–144.9) 54.7 (24.8–77.9) 67.7 (46.2–115.1)
3-Phenyllactic acid 54.7 (45.0–81.4) 47.7 (42.4–57.7)†# 77.6 (58.5–115.2)*# 65.7 (57.3–75.1)
3-(4-Hydroxyphenyl)-
lactic acid
303 (222–377) 261 (206–307) 300 (232–478) 302.5 (264–393)
aThe majority of bacteria belong to the four phyla found in the human gut (Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria).
bCodes of chemical substances are given in parenthesis.
cMedian values (ng/ml) followed by the interquartile range in parenthesis (25th and 75th percentiles).
*p < 0.05 significance compared to healthy controls.
†p < 0.05 significance between FMF and PU patients.
#p < 0.05 significance between FMF stages.
§Fatty acids affected by host metabolism.
Table 1 | Continued
Substance Potential microbial sourcea Healthy controls FMF remission FMF attack PU patients
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studied, and the resulting scatterplot of DA calculations is shown 
in Figure 1. DA of a data matrix consisting of 94 cases as statistical 
units (13 cases of FMF remission, 24 – acute FMF, 14 – PU, and 43 – 
healthy controls) and the concentration of 35 microbial products in 
peripheral blood (Table 1) as statistical variables revealed a 100% 
accuracy of disease classification (Table 2).
The statistical significance of the DA model was also supported 
by the Wilks’ lambda test (Table 3).
The DA model, which is based on the set of markers of microbial 
origin, has good predictive accuracy resulting in excellent separa-
tion of the diseased and healthy cohorts studied. This statistical 
analysis also supports the hypothesis that changes in the human 
metabolome are disease-specific.
dIScuSSIon
In this work, we have investigated the influence of human gut micro-
biota on the human metabolome through a pioneering approach 
involving the quantification of bacterial structural components, 
long chain fatty acids (LCFAs), present in human systemic circu-
lation. The concentration of 30 molecules comprising hydroxy, 
branched, cyclopropyl and unsaturated fatty acids and aldehydes 
was assessed using GS/MS analysis of peripheral blood from healthy 
control subjects and was compared with the corresponding values 
in patients with a hereditary autoinflammatory disorder (FMF) 
and in patients with PU caused by H. pylori infection (94 subjects 
in total). The concentration of five phenolic compounds was also 
measured in these cohorts. Statistically significant differences were 
observed in the level of LCFAs and phenolics in healthy and disease 
states. Moreover, DA analysis confirmed that this set of variables is 
sufficient for accurate classification of disease state and suggests that 
metabolomic profiles based on bacterial structural components 
and metabolites are disease-specific.
Previously, we established that the gut microbial community 
is restructured in FMF (Khachatryan et al., 2008). The present 
work complements this finding and suggests that the structural 
changes observed are accompanied by corresponding changes in 
the human systemic metabolome. In particular, we note a statis-
tically significant increase of the γ-proteobacteria-related SSU 
rRNA sequences in the gut community of FMF patients in remis-
sion, compared to control patients (Khachatryan et al., 2008). In 
the present work, the concentration of specific markers for this 
group of bacteria (2hC12:0, 3hC12:0, and C17cyc in Table 1) also 
increased significantly in the metabolome of FMF patients. A simi-
lar trend was observed for PU patients (Table 1). The markers 
2hC12:0 and 3hC12:0 are precursors of lipid A and subsequently 
lipopolysaccharide (LPS) biosynthesis in one of the representa-
tives of γ-proteobacteria, Pseudomonas aeruginosa (Goldman et al., 
1988). However, the monomers themselves are only weak inducers 
of inflammation and the pro-inflammatory effect. For example, 
the effect of 3hC12:0 can only be seen at much higher concentra-
tions than detected in this work (Soydan et al., 2006). It may be 
important to note that the monomers detected are released by the 
acid catalyzed methanolysis used during the analysis procedure, 
and the original compound in blood may well be LPS, which is 
an extremely potent inducer of the inflammatory cascade even at 
low concentrations (Beutler and Rietschel, 2003). The microbial 
unSaturated fatty acIdS
In contrast to iso- and anteiso-fatty acids, the levels of unsaturated 
fatty acids were highly variable among the groups studied. The high-
est concentration of unsaturated fatty acids was detected mainly 
in PU patients suggesting an overrepresentation of the associated 
microorganisms in these patients, with the exception of C15:1d9, 
which was lower compared to all other groups (Table 1). The val-
ues for FMF remission patients and healthy controls were approxi-
mately equal. In the FMF attack state, levels of unsaturated acids 
were reduced compared to other groups (or differences were not 
statistically significant) and only cis-9-heptadecenoic acid, an indica-
tor of Candida albicans, was increased compared to the controls.
aldeHydeS
Measurement of this group of compounds in the human metabo-
lome revealed a significantly higher concentration of myristic alde-
hyde, an indicator of Eubacterium lentum and Bifidobacterium, in PU 
patients compared to other groups studied (Table 1). Elevated con-
centrations of iso-myristic, oleic, and anteiso-heptadecanoic alde-
hydes were found in blood of PU patients compared to FMF patients 
in remission. The latter substance along with iso-palmitic aldehyde 
was also detected at higher concentrations in patients in the acute 
phase of FMF. Both of these markers are indicators of Eubacterium 
and Propionibacterium. In all disease cohorts the concentration of 
 cis-vaccenic aldehyde was uniformly reduced compared to control.
pHenolIc coMpoundS
These are products of dietary aromatic amino acid transforma-
tion by intestinal microbiota. A number of significant differences 
were also observed in profiles of these compounds, particularly 
in benzoic, 3-phenylpropionic, and 3-phenyllactic acids (Table 1). 
Benzoic acid increased in both FMF disease states compared to 
the healthy control group, with considerable elevation of levels in 
blood of PU patients. In contrast, the level of 3-phenylpropionic 
acid was reduced in the diseased cohorts compared to the normal 
controls, reaching a four-fold reduction in PU patients. In particu-
lar, 3-phenyllactic acid levels significantly increased in the FMF 
attack state compared to normal controls or FMF remission. In 
the latter group, the level of 3-phenyllactic acid was significantly 
lower than in PU patients.
dIScrIMInant functIon analySIS
Although the pair-wise comparisons revealed significant changes 
in the human metabolome due to disease, it is not clear if these 
changes are disease-specific or not. Evidence that some groups of 
microorganisms may be over- or under-represented in these diseases 
provides indirect support for disease-specific changes (Table 1). If 
true, then the level of specific microbial products should correlate 
with those originating from the same group of microorganisms. 
In addition, we have demonstrated previously that in the case of 
FMF patients the gut microbiota is restructured (Khachatryan et al., 
2008), which possibly leads to the specific shifts observed in the 
range of microbial compounds and metabolites produced.
To test this hypothesis, the raw data were subjected to multi-
variate DA to determine the distribution of low-weight microbial 
patterns from the complex datasets obtained from each group 
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Table 3 | Wilks’ lambda test of class center separation.
Test of Wilks’ lambda Chi-square discriminant Significance 
function (s)   function
1 through 3 0.007 360.316 105 0.000
2 through 3 0.095 172.905 68 0.000
3 0.402 67.021 33 0.000
Table 2 | Classification table of correct estimates based on 35 variables set.
Groups da accuracy (%)
 Predicted group membership 
Total (N)
  Control (N) FMF attack (N) FMF remission (N) PU (N) 
Control 100.0 43 0 0 0 43
FMF attack 100.0 0 24 0 0 24
FMF remission 100.0 0 0 13 0 13
PU 100.0 0 0 0 14 14
Total 100.0 43 24 13 14 94
FiGUre 1 | Scatterplot of da model based on concentration of fatty acids and phenolics in blood. Number of variables in model: 35; grouping – 4 groups. Root 
1, 2 – discriminant functions 1 and 2 (first and second canonical roots). Healthy controls are shown in blue circles; FMF attack – in green circles; FMF remission – in 
yellow circles; and PU – in purple circles. Class centers are shown in dark blue squares.
 community structure shifts observed in disease may not only result 
in microbial compounds that are presently considered as neutral to 
the host but also in products potentially contributing to the diseased 
state. This may, in part, explain how the normal gut microbiota can 
acquire pathogenic properties through the selection and restructur-
ing of microbial community structure in the diseased host (Garrett 
et al., 2007, 2010).
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is one of the major contributors to a diverse range of endogenous 
metabolites found in the human metabolome. The best example 
of metabolites produced by the gut microbiota are probably short 
chain fatty acids produced in large quantities, part of which such 
as butyrate is metabolized in situ by colonic epithelium and the 
remainder including acetate and propionate enter systemic cir-
culation to serve the energy and biosynthetic needs of the host 
(Cummings, 1994). The role of these end products of bacterial 
metabolism is not limited to supplying the catabolic and anabolic 
needs of the host but may also have clinical implications. The effect 
of decreased availability of butyrate, for example, may result in a 
reduction of their protective effect toward bowel cancer in inflam-
matory bowel diseases (Thibault et al., 2010).
The range of systemic bacterial metabolites under investigation 
is constantly increasing in order to find suitable biomarkers for 
evaluation of various aspects of human health. A novel aspect of 
this study is that, in addition to the products of bacterial metabo-
lism such as phenolic compounds, we also attempted to quan-
tify a broad range of other molecules in the human metabolome, 
which are not the bacterial metabolites per se but are structural 
components of microbial cells. Because of the extremely potent 
effects on the host that have been discovered more than a century 
ago, the best-studied example among the bacterial structural com-
ponents is LPS. It is a major component of the outer membrane 
in Gram-negative bacteria and consists of lipid A (or endotoxin), 
the core oligosaccharide, and the O antigen (Raetz and Whitfield, 
2002). In addition to the more obvious cases of infectious disease, 
plasma LPS concentration is responsive to diet suggesting that diet-
related shifts in the population structure of gut microbiota may 
be responsible for this phenomenon because dietary LPS intake 
was similar between the diets (Ghanim et al. 2009). We also found 
that LPS-related monomer levels increased in plasma of FMF and 
PU patients. Restructured microbiota with overrepresentation of 
γ-proteobacteria (Khachatryan et al., 2008) and impaired gut bar-
rier function due to chronic inflammation in these diseases may 
lead to an elevated level of these bacterial structural components 
in the human metabolome. We established earlier that in FMF the 
level of systemic antibodies toward antigens of gut commensal 
bacteria is elevated suggesting that the gut barrier function may be 
compromised in this disease (Manukyan et al., 2008b).
Very little is known about the concentration of other bacte-
rial structural compounds entering into, and circulating in, the 
human metabolome. In this respect, LCFAs represent good candi-
dates for measuring the impact of changes in the gut microbiota 
on the human metabolome. The repertoire of endogenous LCFAs 
in humans (and eukaryotes in general) is limited because the 
biosynthetic needs are served by a single type I fatty acid synthase 
(Lomakin et al., 2007; Maier et al., 2008), whilst bacteria synthe-
size a wide diversity of different types of fatty acids through type 
II fatty acid synthase systems (Lu et al., 2004). The LCFAs profile 
of a given bacterium is highly specific and GC/MS may serve as 
a rapid and sensitive method for identification or detection of 
bacteria (Li et al., 2010). Bacterial ecosystems may, therefore, be 
characterized by unique sets of LCFAs “fingerprints” specific for 
given microbial communities. In this work, although not meas-
ured directly in the gut microbiota, the bacterial LCFAs finger-
prints observed in the human metabolome were highly  specific 
The concentration of phenolic compounds in the normal 
human gut is usually high (Jenner et al., 2005) and these are mainly 
the products of degradation of aromatic amino acids in the large 
intestine. Phenylpropionate, phenylacetate, and phenyllactate that 
we measured in systemic circulation in this study are the prod-
ucts of phenylalanine catabolism by gut bacteria (Macfarlane and 
Cummings, 1991). The pool of benzoic acid, in contrast, arises 
from several sources, including direct dietary intake (berries and 
food preservatives) and as a byproduct of dietary phenylalanine 
and polyphenols metabolism in gut bacteria. The only hydroxy-
phenyl-containing molecule measured, hydroxyphenyllactate, is the 
product of endogenous tyrosine metabolism, ingested as a dietary 
component or obtained by hydroxylation of phenylalanine. The 
level of hydroxyphenyllactic acid is elevated in patients with inher-
ited deficiency of the enzyme p-hydroxyphenylpyruvate oxidase 
(Wishart et al., 2009) and we observed no difference in the level 
of this compound among our cohorts. Phenolic compounds may 
influence a range of cellular functions including differentiation, 
apoptosis, mitochondrial function, and inflammation (Li et al., 
2004; Karlsson et al., 2005; Fedotcheva et al., 2008).
We found that the plasma concentrations of phenylpropion-
ate in both PU and FMF attack state patients were significantly 
reduced (Table 1). This compound inhibits the TNF-α-stimulated 
induction of cyclooxygenase-2 (COX-2) protein in HT29 cells 
leading to the suppression of COX-2-catalyzed prostaglandin bio-
synthesis involved in inflammation (Karlsson et al., 2005). Thus 
the lower concentration of phenylpropionate found in PU and 
FMF patients may be a factor contributing to the maintenance of 
chronic inflammation in these two diseases. Interestingly, despite 
that these phenyl-containing compounds are all derived from 
the catabolism of the same amino acid, phenylalanine, the level 
of resulting products is very different between cohorts. This may 
reflect the structural differences in microbiota that possess differ-
ent metabolic routes or catabolic efficiencies in transformation of 
phenyl-containing compounds.
Benzoic acid is detoxified as a conjugate with glycine and excreted 
through the hepatic and renal routes (Tremblay and Qureshi, 1993). 
The rate of conjugation of benzoic acid with glycine varies among 
subjects but it is normally distributed (Temellini et al., 1993). We 
found a statistically significant increase in systemic benzoate con-
centration in all disease cohorts compared to control (Table 1). Due 
to its comparatively larger mass the liver is the main route of ben-
zoylglycine disposal, but, there is no indication that liver function 
is compromised in these two diseases, which may result in a higher 
residual benzoate level. Moreover, the limiting step in the forma-
tion of hippurate is availability of glycine (Beliveau and Brusilow, 
1987) and there is no literature data suggesting any abnormality 
of glycine metabolism in these two diseases. Therefore, the statis-
tically significant increase in systemic benzoic acid concentration 
observed in PU and FMF patients may be due to a restructured gut 
microbiota, with a higher proportion of gut bacteria that are more 
efficient at degradation of dietary plant polyphenols.
The human metabolome results from the combination of 
genetic and environmental components such as diet, ethnicity 
and geographical location, disease, and other factors (Rezzi et al., 
2007; Holmes et al., 2008; Li et al., 2008). Being tightly integrated 
within the host in a symbiotic relationship, the gut microbiome 
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for the cohorts studied (Figure 1). This observation  correlates 
well with our previous analyses of microbial community structure 
performed using different SSU rRNA-based molecular ecology 
approaches (Khachatryan et al., 2008). Interestingly, the LCFAs 
profile in the metabolome of PU patients suggests extensive 
structural changes in the gut microbiota involving other bacte-
rial populations in the lower parts of the GIT rather than a local 
effect of a single infectious agent, H. pylori, in the stomach. This 
suggests that further investigations of community structure in 
lower parts of the GIT in this disease using molecular ecology 
approaches may be useful.
Need to note, however, that not all fatty acids measured in the 
metabolome are exclusively of microbial origin. Some unsaturated 
fatty acids such as myristoleic acid (cis-9-tetradecenoic acid) may 
also be formed endogenously from the dietary myristic acid by 
the enzyme stearoyl-CoA desaturase (delta-9 desaturase; Wishart 
et al., 2009). This enzyme is a key regulator of lipid metabolism and 
plays an important role in human metabolic disease (Sampath and 
Ntambi, 2008). The high-saturated as well as monounsaturated-fat 
diets can increase its expression and the contribution of microbial 
fatty acids on this highly regulated enzyme has to be elucidated. 
Another unsaturated fatty acid, cis-11-eicosenoic acid, is found in 
a variety of plant oils (Wishart et al., 2009) and part of it in the 
human metabolome may be of dietary origin. Increased concentra-
tion of eicosenoic acid in red blood cells is associated with autism 
in children (Bu et al., 2006). Thus the microbially produced fatty 
acids may intercalate into the endogenous fatty acid metabolism 
affecting the human health.
In conclusion, in this study we have established that significant 
concentrations of microbial LCFAs present in the human metabo-
lome and that the profile of these LCFAs is specific for the healthy 
and diseased states. The LCFA profile therefore may potentially 
serve as a biomarker for disease.
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